Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone Liposome in R/R DLBCL
NCT05875428Phase 2Recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jul 2023
- Primary completion
- Dec 2024
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of mitoxantrone hydrochloride liposome in diffuse large B-cell lymphoma (DLBCL), sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Jul 2023; status: recruiting.
02
Drugs
mitoxantrone hydrochloride liposome
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05875428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05875428.